FBRX
Forte Biosciences, Inc.23.27
+1.31+5.97%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
291.50MP/E (TTM)
-Basic EPS (TTM)
-0.08Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Forte's Q2 loss, FB102 trials advance
Forte Biosciences reported Q2 2025 net loss of $11.2 million, with R&D expenses climbing to $8.5 million from $5.6 million year-over-year, fueled by FB102 clinical trials in celiac disease and vitiligo. The company raised $71.6 million via public offering, bolstering its cash position to $106.1 million. Three FB102 readouts loom in 2026. Clinical risks persist amid autoimmune uncertainties.
10-Q
Q2 FY2025 results
Forte Biosciences narrowed its Q2 operating loss to $11.6M from $12.8M y/y, driven by lower G&A expenses that offset higher R&D spending on FB102 trials, while net loss improved to $11.2M from $12.5M y/y (derived). For the half-year, operating expenses climbed 34% y/y to $27.7M, reflecting ramped-up clinical work, yielding a net loss of $26.9M versus $19.9M last year (derived). Cash swelled to $106.1M at quarter-end, bolstered by a $75M public offering in June—enough to fund operations through mid-2026. No debt burdens the balance sheet. Yet clinical setbacks could derail FB102's autoimmune promise.
8-K
Forte prices $75M offering
Forte Biosciences priced a $75 million public offering on June 24, 2025, selling 5.63 million shares at $12.00 each and pre-funded warrants for 619,606 shares at $11.999, with underwriters holding a 30-day option for 937,508 more shares. Net proceeds of $70 million, or $80.5 million if fully exercised, will fund clinical development and operations into 2027. Yet market conditions could delay closing, set for June 26.
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
FATE
Fate Therapeutics, Inc.
1.09-0.03
FBIO
Fortress Biotech, Inc.
3.51+0.19
FBLG
FibroBiologics, Inc.
0.24-0.02
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
LBRX
LB Pharmaceuticals Inc
19.82-0.04
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
VTYX
Ventyx Biosciences, Inc.
8.21-0.13
XLO
Xilio Therapeutics, Inc.
0.65+0.00